Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide

Shinya Fujisawa; Ryuzo Ohno; Kazuyuki Shigeno; Naohi Sahara; Satoki Nakamura; Kensuke Naito; Miki Kobayashi; Kaori Shinjo; Akihiro Takeshita; Yoshinari Suzuki; Hisakuni Hashimoto; Kenji Kinoshita; Masahito Shimoya; Toshikazu Kaise; Kazunori Ohnishi

首页> 外文期刊>Cancer Chemotherapy and Pharmacology >Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide

【24h】

Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide

机译：三氧化二砷治疗日本复发或难治性急性早幼粒细胞白血病患者中砷物质的药代动力学

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

To investigate the pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia (APL) treated with arsenic trioxide (ATO) at a daily dose of 0.15 mg/kg.

机译：目的研究日剂量0.15 mg / kg的三氧化二砷（ATO）治疗的复发或难治性急性早幼粒细胞白血病（APL）的日本患者中砷物质的药代动力学。

著录项

来源
《Cancer Chemotherapy and Pharmacology》 |2007年第4期|485-493|共9页
作者
Shinya Fujisawa; Ryuzo Ohno; Kazuyuki Shigeno; Naohi Sahara; Satoki Nakamura; Kensuke Naito; Miki Kobayashi; Kaori Shinjo; Akihiro Takeshita; Yoshinari Suzuki; Hisakuni Hashimoto; Kenji Kinoshita; Masahito Shimoya; Toshikazu Kaise; Kazunori Ohnishi;
展开▼
作者单位

Department of Medicine III Hamamatsu University School of Medicine Hamamatsu Japan;

Aichi Cancer Center Hospital Nagoya Aichi Japan;

Department of Medicine III Hamamatsu University School of Medicine Hamamatsu Japan;

Department of Medicine III Hamamatsu University School of Medicine Hamamatsu Japan;

Department of Medicine III Hamamatsu University School of Medicine Hamamatsu Japan;

Department of Medicine III Hamamatsu University School of Medicine Hamamatsu Japan;

Department of Medicine III Hamamatsu University School of Medicine Hamamatsu Japan;

Department of Medicine III Hamamatsu University School of Medicine Hamamatsu Japan;

Department of Laboratory Medicine Hamamatsu University School of Medicine Hamamatsu Japan;

Pharmacy Department Hamamatsu University Hospital Hamamatsu Japan;

Pharmacy Department Hamamatsu University Hospital Hamamatsu Japan;

Laboratory of Environmental Chemodynamics Tokyo University of Pharmacy and Life Science Hachioji Tokyo Japan;

Laboratory of Environmental Chemodynamics Tokyo University of Pharmacy and Life Science Hachioji Tokyo Japan;

Laboratory of Environmental Chemodynamics Tokyo University of Pharmacy and Life Science Hachioji Tokyo Japan;

Department of Medicine III Hamamatsu University School of Medicine Hamamatsu Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. [J] . Fox E, Razzouk BI, Widemann BC, Blood: The Journal of the American Society of Hematology . 2008,第2期

机译：三氧化二砷在难治性或复发性急性白血病（包括急性早幼粒细胞白血病或淋巴瘤）的儿童和青少年中的1期试验和药代动力学研究。
2. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. [J] . Thirugnanam R, George B, Chendamarai E Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2009,第11期

机译：比较三氧化二砷诱发并合并自体干细胞移植或三氧化二砷治疗的急性急性早幼粒细胞白血病患者的临床结局。
3. Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide [J] . Guo Meihua, Wang Bin, Liu Shuchuan, Expert review of clinical pharmacology . 2019,第1a6期

机译：单粒砷砷治疗砷红细胞红细胞的时间过程
4. Arsenic speciation in whole blood samples from Acute Promyelocytic Leukemia (APL) patients after tetra-arsenic tetra-sulfide therapy [C] . B. Chen, W.T. Corns, P.B. Stockwell International Congress on Arsenic in the Environment . 2014

机译：在四砷四硫化物治疗后，急性早幼细胞白血病（APL）患者的全血样品中的砷形式
5. Characterization of the novel arsenical darinaparsin (ZIO-101, S-dimethylarsino-glutathione) as a more potent inducer of oxidative stress and apoptosis than arsenic trioxide in acute promyelocytic leukemia. [D] . Kourelis, Maria. 2009

机译：在急性早幼粒细胞白血病中，新型砷化降火药（ZIO-101，S-二甲基ar-谷胱甘肽）比三氧化二砷更有效地诱导氧化应激和细胞凋亡。
6. Clinical Trials and Observations: Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia including acute promyelocytic leukemia or lymphoma [O] . Elizabeth Fox, Bassem I. Razzouk, Brigitte C. Widemann, -1

机译：临床试验和观察：三氧化二砷在难治性或复发性急性白血病（包括急性早幼粒细胞白血病或淋巴瘤）的儿童和青少年中的一期试验和药代动力学研究
7. Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide [O] . Shinya Fujisawa, Ryuzo Ohno, Kazuyuki Shigeno, 2006

机译：用三氧化二砷治疗的日本复发或难治急性早产细胞白血病砷的药代动力学

Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide

摘要

著录项

相似文献

相关主题

期刊订阅